Triple therapy: still an option?

Back

ESC Premium Access

Triple therapy: still an option?

Session: Dual versus Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Stenting

Topic: Pharmacotherapy

Speaker: Professor K. Huber (Vienna, AT)

Event: ESC Congress 2020

Congress Presentation

About the speaker

Professor Kurt Huber

Sigmund Freud University Vienna, FacutlVice Dean of Researchy fo Medicine, Vienna (Austria)

54 presentations

10 followers

3 more presentations in this session

A historical perspective: why we opted triple therapy for so long and what made us change our mind.

Speaker: Professor D. Angiolillo (Jacksonville, US)

Access

Slides

Video

Dual versus triple antithrombotic therapy, does trial design make the difference?

Speaker: Professor R. Storey (Sheffield, GB)

Access

Slides

Video

Dual versus triple antithrombotic therapy - The fine art of personalised medicine.

Speaker: Professor R. De Caterina (Pisa, IT)

Access

Slides

Video

Access the full session

Dual versus Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Stenting

Speakers: Professor K. Huber, Professor D. Angiolillo, Professor R. Storey, Professor R. De Caterina

Access

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

Triple therapy: still an option?

About the speaker

Professor Kurt Huber

3 more presentations in this session

A historical perspective: why we opted triple therapy for so long and what made us change our mind.

Dual versus triple antithrombotic therapy, does trial design make the difference?

Dual versus triple antithrombotic therapy - The fine art of personalised medicine.

Access the full session

Dual versus Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Stenting

About the event

ESC Congress 2020

ESC 365 is supported by